Oral administration of eugenol oleate cures experimental visceral leishmaniasis through cytokines abundance
Abstract
No abstract availableKeywords
Funding Information
- CSIR
This publication has 39 references indexed in Scilit:
- Relapse after Treatment with Miltefosine for Visceral Leishmaniasis Is Associated with Increased Infectivity of the Infecting Leishmania donovani StrainmBio, 2013
- Leishmania virulence factors: focus on the metalloprotease GP63Microbes and Infection, 2012
- Leishmaniasis Worldwide and Global Estimates of Its IncidencePLOS ONE, 2012
- RETRACTED: TLR signaling-mediated differential histone modification at IL-10 and IL-12 promoter region leads to functional impairments in tumor-associated macrophagesCarcinogenesis, 2011
- Unresponsiveness to AmBisome in some Sudanese patients with kala-azarTransactions of the Royal Society of Tropical Medicine and Hygiene, 2007
- Current understandings on the immunology of leishmaniasis and recent developments in prevention and treatmentBritish Medical Bulletin, 2005
- Activation of p38 Mitogen-Activated Protein Kinase AttenuatesLeishmania donovaniInfection in MacrophagesInfection and Immunity, 2002
- Immunomodulatory Role of Interleukin-10 in Visceral Leishmaniasis: Defective Activation of Protein Kinase C-Mediated Signal Transduction EventsInfection and Immunity, 2001
- Miltefosine, an Oral Agent, for the Treatment of Indian Visceral LeishmaniasisNew England Journal of Medicine, 1999
- Specific Inhibitors of p38 and Extracellular Signal‐Regulated Kinase Mitogen‐Activated Protein Kinase Pathways Block Inducible Nitric Oxide Synthase and Tumor Necrosis Factor Accumulation in Murine Macrophages Stimulated with Lipopolysaccharide and Interferon‐γThe Journal of Infectious Diseases, 1999